Short Interest in Pharming Group (NASDAQ:PHAR) Increases By 165.6%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 25,500 shares, a growth of 165.6% from the October 31st total of 9,600 shares. Based on an average trading volume of 6,600 shares, the days-to-cover ratio is presently 3.9 days.

Wall Street Analyst Weigh In

PHAR has been the topic of several recent analyst reports. Oppenheimer reduced their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, October 24th.

Pharming Group Price Performance

Shares of PHAR stock opened at $7.58 on Thursday. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20. The stock has a market capitalization of $513.81 million, a PE ratio of -30.31 and a beta of 0.13. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock’s fifty day moving average is $8.26 and its 200-day moving average is $8.25.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.